On Monday, Arcus Biosciences cleared an important performance benchmark, with its Relative Strength (RS) Rating jumping into the 80-plus percentile with an improvement to 85, up from 80 the day before.
Looking For The Best Stocks To Buy And Watch? Start Here
This exclusive rating from Investor's Business Daily tracks market leadership with a 1 (worst) to 99 (best) score. The grade shows how a stock's price movement over the trailing 52 weeks holds up against all the other stocks in our database.
Over 100 years of market history shows that the best stocks often have an RS Rating of at least 80 as they begin their biggest price moves.
While now is not an ideal time to jump in, see if the stock manages to offer and clear an appropriate buy point.
The company reported 0% EPS growth in the latest quarterly report, while sales growth came in at 310%.
Arcus Biosciences earns the No. 127 rank among its peers in the Medical-Biomed/Biotech industry group. Aurinia Pharmaceuticals, Halozyme Therapeutics and Incyte are among the top 5 highly rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
Stocks With Rising Relative Strength Ratings
